News of the high effectiveness rates in vaccine trials signals what may actually be the beginning of the end of this tumultuous year.
According to the WHO, over 150 vaccines are being developed globally. The EU has approved contracts with four companies and has secured millions of doses on behalf of all member states. Contracts have been signed with AstraZeneca, Sanofi-GSK, Johnson & Johnson, CureVac, BioNTech-Pfizer and Moderna.
These agreements will allow member states to buy 160 million doses of the Moderna vaccine, 300 million of the AstraZeneca and Sanofi-GSK vaccines and 200 million of Johnson & Johnson. Also, the EU will be covering for the initial purchase of 200 million doses on behalf of all EU member states, for vaccines provided by BioNTech-Pfizer and another 225 million from CureVac.